Startup Cognixion, which has developed a noninvasive brain-computer interface, has begun a clinical trial for patients with ...

More recently, axonal loss has also been recognized as a feature of the disease, but the relationships between axonal loss, plaque formation and demyelination are unclear. In a postmortem study of ...

Axon Enterprise Inc.’s stock was up 15% as one of the top gainers in the S&P 500 on Wednesday after the Taser maker said budget cuts in Washington may help its business as it played up its prospects ...

Chronic, irreversible motor disability in patients with multiple sclerosis (MS) correlates with axonal pathology rather than demyelination, according to new research. During the early stages of MS ...

Axon Enterprise (AXON) closed the latest trading day at $652.18, indicating a -0.19% change from the previous session's end. This move was narrower than the S&P 500's daily loss of 0.51%.

Axon Enterprise (AXON) closed the latest trading day at $665.08, indicating a -0.62% change from the previous session's end. The stock's performance was behind the S&P 500's daily loss of 0.27%.

Previously, macrophages were thought to have a pathogenic role in diabetes and were mainly reacting to axon loss. But Hakim, Woolf, and colleagues observed just the opposite. "To our great ...

Each year, according to the National Institutes of Health (NIH), millions of people in the U.S. are affected by spinal cord ...

Including Wednesday's rally, Axon's stock has gained back much of its loss for the year, but the stock remains 3.7% lower so far in 2025, while the S&P 500 SPX has risen 1.3%.